Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation. [PDF]
Fan J, Song Y.
europepmc +1 more source
Interaction between Poly(ADP-ribose) polymerase-1 and α-synuclein pathology in Parkinson's disease. [PDF]
Zhang P, Li Q, Diao X, Zeng S.
europepmc +1 more source
PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination. [PDF]
Wang J +9 more
europepmc +1 more source
Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review. [PDF]
Dima G +8 more
europepmc +1 more source
Targeting m<sup>6</sup>A RNA methylation to sensitize cancer cells to DNA-damaging therapies. [PDF]
Cesaro B +4 more
europepmc +1 more source
Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells. [PDF]
Ribeiro J +14 more
europepmc +1 more source
Parylation dependent nuclear export of HMGB1 via exportin 1 contributes to morphine tolerance
Yuexin Liang +11 more
openalex +1 more source
Poly(ADP-ribose) glycohydrolase enforces p21 degradation via dePARylation to promote gastric cancer progression. [PDF]
Hu Y +23 more
europepmc +1 more source

